Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent

Tonix Pharmaceuticals Holding (Nasdaq:TNXP) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 12/948,828, “Methods and compositions for treating symptoms associated with posttraumatic stress disorder using cyclobenzaprine,” covering the use of Tonmya*, or TNX-102 SL, for the treatment of post traumatic stress disorder (PTSD).
As quoted in the press release:

This patent protects the method of using Tonmya’s active ingredient cyclobenzaprine to treat PTSD. The Tonmya eutectic formulation of cyclobenzaprine was designed for sublingual (under-the-tongue) administration to enable transmucosal absorption of cyclobenzaprine, which bypasses first pass liver metabolism. Other oral formulations of cyclobenzaprine are approved for short-term use (two-three weeks) for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Click here to read the full press release.